Comparison of integrin αvβ3 expression and glucose metabolism in primary and metastatic lesions in cancer patients:: A PET study using 18F-galacto-RGD and 18F-FDG
Comparison of integrin αvβ3 expression and glucose metabolism in primary and metastatic lesions in cancer patients:: A PET study using 18F-galacto-RGD and 18F-FDG
复制标题
DOI：
10.2967/jnumed.107.045864
复制
发表时间：
2008-01-01
影响因子：
9.3
通讯作者：
Schwaiger, Markus
中科院分区：
文献类型：
--
作者：
Beer, Ambros J.;Lorenzen, Sylvie;Schwaiger, Markus
α（v）β（3）的表达和葡萄糖代谢在许多恶性病变中上调，并且已知两者都与侵袭性表型相关。我们评估了使用F-18-galacto-RGD和F-18-FDG的PET评估α（v）β（3）表达和葡萄糖代谢是否为癌症患者提供了补充信息。研究方法：18例原发性或转移性癌症患者（非小细胞肺癌[NSCLC]，n = 10;肾细胞癌，n = 2;直肠癌，n = 2;其他，n = 4）使用F-18-半乳糖-RGD和F-18-FDG进行PET检查。标准化摄取值（SUV）通过感兴趣体积分析得出。使用线性回归分析比较所有病变（n = 59; NSCLC，n = 39）以及原发灶（n = 14）和转移至骨（n = 11）、肝脏（n = 10）和其他器官（n = 24）的F-18-Galacto-RGD和F-18-FDG PET结果。结果：F-18-半乳糖-RGD PET与临床分期相比的敏感性为76%。F-18-FDG的SUV范围为1.3至23.2（平均值+/-SD，7.6 +/-4.9），并且显著高于F-18-半乳糖-RGD的SUV（范围，0.3 - 6.8;平均值+/-SD，2.7 +/-1.5; P <0.001）。18F-FDG和F-18-galacto-RGD的SUV值在所有病灶中均无显著相关性（r = 0.157; P = 0.235），在原发灶、骨转移灶和软组织转移灶中亦无显著相关性（P> 0.05）。对于非小细胞肺癌的病变亚组，（18）FDG和F-18-半乳糖-RGD吸收之间存在弱相关性（r = 0.353; P = 0.028）。结论：恶性肿瘤中F-18-galacto-RGD和F-18-FDG的示踪摄取并不密切相关。虽然F-18-FDG PET对肿瘤分期更敏感，但F-18-半乳糖-RGD PET需要进一步评估，以用于抗血管生成或α（v）β（3）靶向药物的靶向分子治疗的计划和反应评估。
The expression of alpha(v)beta(3) and glucose metabolism are upregulated in many malignant lesions, and both are known to correlate with an aggressive phenotype. We evaluated whether assessment of alpha(v)beta(3) expression and of glucose metabolism with PET using F-18-galacto-RGD and F-18-FDG provides complementary information in cancer patients. Methods: Eighteen patients with primary or metastatic cancer (non-small cell lung cancer [NSCLC], n = 10; renal cell carcinoma, n = 2; rectal cancer, n = 2; others, n = 4) were examined with PET using F-18-galacto-RGD and F-18-FDG. Standardized uptake values (SUVs) were derived by volume-of-interest analysis. F-18-Galacto-RGD and F-18-FDG PET results were compared using linear regression analysis for all lesions (n = 59; NSCLC, n = 39) and for primaries (n = 14) and metastases to bone (n = 11), liver (n = 10), and other organs (n = 24) separately. Results: The sensitivity of F-18-galacto-RGD PET compared with clinical staging was 76%. SUVs for F-18-FDG ranged from 1.3 to 23.2 (mean +/- SD, 7.6 +/- 4.9) and were significantly higher than SUVs for F-18-galacto-RGD (range, 0.3-6.8; mean +/- SD, 2.7 +/- 1.5; P < 0.001). There was no significant correlation between the SUVs for 18F-FDG and F-18-galacto-RGD for all lesions (r = 0.157; P = 0.235) or for primaries, osseous or soft-tissue metastases separately (P > 0.05). For the subgroup of lesions in NSCLC, there was a weak correlation between (18)FDG and F-18-galacto-RGD uptake (r = 0.353; P = 0.028). Conclusion: Tracer uptake of F-18-galacto-RGD and F-18-FDG does not correlate closely in malignant lesions. Whereas F-18-FDG PET is more sensitive for tumor staging, F-18-galacto-RGD PET warrants further evaluation for planning and response evaluation of targeted molecular therapies with antiangiogenic or alpha(v)beta(3)-targeted drugs.